Previous 10 | Next 10 |
Initiation of Phase 2b clinical trial anticipated in Q4 2020 Trial to enroll approximately 100 patients hospitalized with COVID-19 Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceu...
WESTMINSTER, Colo., Oct. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the promotion of Debra Marshall, MD, FA...
ARCA Biopharma (ABIO) has submitted an Investigational New Drug application under the Coronavirus Treatment Acceleration Program ((CTAP)) to evaluate AB201 for the treatment of patients hospitalized with COVID-19.Pending FDA feedback, ARCA anticipates to initiate the Phase 2b p...
WESTMINSTER, Colo., Sept. 21, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced it has submitted an Investigational ...
Marinus Pharmaceuticals (NASDAQ: MRNS ) +61% after ganaxolone successful in pivot study in rare type of epilepsy. More news on: Marinus Pharmaceuticals, Inc., Plus Therapeutics, Inc., Tiziana Life Sciences PLC, Stocks on the move, , Read more ...
VBL Therapeutics reports progress for ovarian cancer drug candidate VBL Therapeutics ( VBLT ) announced the progress for its Phase 3 OVAL trial for platinum resistant ovarian cancer. The overall survival data from the trial was unblinded and reviewed by the independent Data Safety Monito...
After winding up talks with the FDA to clarify a development path, ARCA biopharma (NASDAQ: ABIO ) announces that it expects to file an IND next month seeking agency sign-off on a Phase 2b clinical trial evaluating AB201 in severely ill COVID-19 patients. The study could launch as early a...
ARCA anticipates filing an IND for AB201 for COVID-19 in September 2020 and initiating Phase 2B clinical testing as early as Q4 2020 WESTMINSTER, CO / ACCESSWIRE / August 12, 2020 / ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine appro...
ARCA biopharma (NASDAQ: ABIO ) : Q2 GAAP EPS of -$0.73 beats by $1.85 . More news on: ARCA biopharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseases ARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4 2020 WESTMINSTER, Colo., Aug. 05, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc...
News, Short Squeeze, Breakout and More Instantly...
Bogota Financial Corp. (BSBK) is expected to report for Q2 2024 Capital Product Partners L.P. (CPLP) is expected to report $0.17 for Q2 2024 Colgate-Palmolive Company (CL) is expected to report $0.87 for Q2 2024 ARCA biopharma Inc. (ABIO) is expected to report for Q2 2024 Barnes G...
Bank of the James Financial Group Inc. (BOTJ) is expected to report for Q2 2024 Electrolux AB ADR (ELUXY) is expected to report $-0.18 for Q2 2024 Coca Cola Femsa S.A.B. de C.V. American Depositary Shares each representing 10 Units (each Unit consists of 3 Series B Shares and 5 Series L S...
NEW YORK, NY / ACCESSWIRE / May 22, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Squarespace, Inc. (NYSE:SQSP)'s sale...